Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK
暂无分享,去创建一个
J. Grimshaw | D. Mattison | M. Watson | L. Bjerre | S. Parlow | David de Launay | Matthew Hogel | Cody D. Black | Simon Parlow
[1] Flora M. Haaijer-Ruskamp,et al. Impact of Safety-Related Regulatory Action on Clinical Practice , 2012, Drug Safety.
[2] J. Sareen,et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults , 2008, Canadian Medical Association Journal.
[3] F. Haramburu,et al. Relevance of a “Dear Doctor letter” to alert healthcare providers to new recommendations for vitamin D administration , 2011, European Journal of Clinical Pharmacology.
[4] Medicines And Healthcare Products Regulatory Agency , 2020, Definitions.
[5] F. Haaijer-Ruskamp,et al. Impact of Safety‐Related Regulatory Action on Drug Use in Ambulatory Care in the Netherlands , 2012, Clinical pharmacology and therapeutics.
[6] J. Samet,et al. Food and Drug Administration , 2007, BMJ : British Medical Journal.
[7] M. Fromm,et al. Implementation of warnings from Dear Doctor Letters (Rote-Hand-Briefe): an analysis of medication data from a large cohort of elderly patients. , 2014, Deutsches Arzteblatt international.
[8] J. Ross,et al. Inconsistencies among European Union Pharmaceutical Regulator Safety Communications: A Cross-Country Comparison , 2014, PloS one.
[9] J. Gurwitz,et al. Communicating safety information to physicians: an examination of dear doctor letters , 2005, Pharmacoepidemiology and drug safety.
[10] Sarah K. Thomas,et al. The Impact of Direct Healthcare Professional Communication on Prescribing Practice in the UK Hospital Setting: An Interrupted Time Series Analysis , 2013, Drug Safety.
[11] C. Thompson. 'Dear Healthcare Professional' letters may not be effective REMS communication tool. , 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[12] B. Fischhoff,et al. Communicating Risks and Benefits: An Evidence Based User's Guide , 2012 .
[13] D. Fife,et al. The impact of wording in “Dear doctor” letters and in black box labels , 2002, Clinical pharmacology and therapeutics.
[14] P. Mol,et al. A Decade of Safety-Related Regulatory Action in the Netherlands , 2010, Drug safety.